Home > What We Do > Participate in a Clinical Trial

study name and who is ELIGIBLE 

 

ANAVEX2-73-AD – Phase 2b/3

WA only

This is a Phase 2b/3 48-week study to evaluate the effects of ANAVEX2-73 on cognition and function after 48 weeks of daily treatment. Anavex2-73 is a novel selective σ1 receptor agonist under investigation to restore homeostasis in patients with serious life-threatening neurodevelopmental and neurodegenerative diseases. The study aims to assess the safety and efficacy of ANAVEX2-73 for the treatment of early Alzheimer’s disease.

For further information please contact Paula Mather or Allae Saade, Clinical Trial Coordinators on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

Who can be involved:

  • Male or female, aged 60 – 85 years inclusive, at the time of informed consent
  • Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • 3 monthly visits
  • 48 week long trial duration
  • Daily medication (oral tablet)
  • Must be able to tolerate MRI scans
  • 33% chance of receiving placebo

For further information please contact Paula Mather or Allae Saade, Clinical Trial Coordinators on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


3D Study – Phase 2 

 WA only

A year long phase 2 study assessing the efficacy, safety and tolerability of Deferiprone in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease as indicated by positive amyloid pathology. The study also aims to determine if Deferiprone lowers brain iron levels in any brain regions and its effect on AD diagnosed patients.

Who can be involved:

  • Male or female, aged 55 years and above at the time of informed consent.
  • Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • 1 year long trial duration
  • 3 monthly visits to Nedlands facility
  • Weekly blood collections at local lab
  • Daily medication twice a day (oral tablet)
  • Must be able to tolerate MRI scan
  • Positive amyloid result on a PET scan

For further information please contact Paula Mather or Allae Saade, Clinical Trial Coordinators on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


COGRX- Phase 2 

WA only

A Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimer’s disease. The Cog R X study aims to determine the effect of preventing amyloid beta oligomer binding to brain cells thereby assessing the hypothesis that cognitive decline in AD is related to toxic effects of beta oligomers.

Who can be involved:

  • Male or female, 50-85 years of age at the time of informed consent.
  • Must be diagnosed with mild  to moderate Alzheimer’s disease
  • Has an identified, reliable, study partner
  • Positive amyloid CSF assessment

What is involved:

  • 6 month long trial duration
  • Visits are weekly for the first month, fortnightly until day 70 then monthly until the end of the trial
  •  Daily medication (oral tablet)
  • Must be able to tolerate MRI scans and CT guided lumbar punctures

For further information please contact Paula Mather or Allae Saade, Clinical Trial Coordinators on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


BAN2401- Phase 3

WA only

A Phase 3 Study evaluating the efficacy of BAN2401 in subjects with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease. The study also aims to assess if BAN 2401 is superior to placebo in reducing brain amyloid levels in AD diagnosed patients.

Who can be involved:

  • Male or female subjects aged≥50 and ≤90 years at the time of informed consent.
  • Must be diagnosed with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
  • Has an identified, reliable, study partner
  • If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

  • 18 month long trial duration
  • Biweekly visits
  • Infusion drug form
  • Must be able to tolerate MRI scans
  • 2 year open label extension available following end of study

For further information please contact Paula Mather or Allae Saade, Clinical Trial Coordinators on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au

* Please note that participants in this study may have a chance of being placed on a placebo medication


Testosterone Study – Phase 2 (TotAL Study) 

NSW & WA only

This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.

Who can be involved:

  • Males aged 60 to 80 years
  • Have memory concerns
  • Does not have a current medical or neurological condition
  • Not currently taking testosterone or diagnosed with hypogonadism
  • Western Australia and New South Wales residents

For further information please contact

WA Contact: Shane Fernandez, Study Coordinator on Ph: 08 6304 3957 or Email: s.fernandez@ecu.edu.au

NSW Contact: Deepal Wakade, Clinical Trial Coordinator on Ph: 02 9812 2974 or Email: deepal.wakade@mq.edu.au

What is involved:

  • 18 month duration
  • Most visits 8 weeks apart
  • Testosterone/placebo will be administered intramuscularly every 8 weeks and fish oil/placebo taken orally every day
  • Medical examinations, memory tests, brain scans, and cerebrospinal fluid collection

* Please note that participants in this study may have a chance of being placed on a placebo medication


Sleep Study 

WA only

This study aims to examine whether improved sleep (better or longer) contributes to better memory and thinking, and improved markers of brain health (assessed using brain imaging). The study will implement a non-pharmacological intervention to improve sleep in older adults who are ‘poor sleepers.

Who can be involved:

  • Male and females aged 60 years to 80 years
  • Residents from Western Australia

For further information about the Sleep Study please contact Jo Shaw, Clinical Trial Coordinator on 08 6457 0264 or email j.shaw@ecu.edu.au